Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation
Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuxim...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2024/5790011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832569211856093184 |
|---|---|
| author | Mary Nauffal Stephen Eng Andrew Lin Alexander Chan Kathryn Mazzerella Sergio Giralt Miguel-Angel Perales Boglarka Gyurkocza |
| author_facet | Mary Nauffal Stephen Eng Andrew Lin Alexander Chan Kathryn Mazzerella Sergio Giralt Miguel-Angel Perales Boglarka Gyurkocza |
| author_sort | Mary Nauffal |
| collection | DOAJ |
| description | Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed. |
| format | Article |
| id | doaj-art-ac05785bddab439abf79bb36007eda2c |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-ac05785bddab439abf79bb36007eda2c2025-02-02T23:02:22ZengWileyCase Reports in Hematology2090-65792024-01-01202410.1155/2024/5790011Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell TransplantationMary Nauffal0Stephen Eng1Andrew Lin2Alexander Chan3Kathryn Mazzerella4Sergio Giralt5Miguel-Angel Perales6Boglarka Gyurkocza7Department of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of PathologyDepartment of Advanced Practice ProvidersDepartment of MedicineDepartment of MedicineDepartment of MedicineIsatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed.http://dx.doi.org/10.1155/2024/5790011 |
| spellingShingle | Mary Nauffal Stephen Eng Andrew Lin Alexander Chan Kathryn Mazzerella Sergio Giralt Miguel-Angel Perales Boglarka Gyurkocza Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation Case Reports in Hematology |
| title | Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation |
| title_full | Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation |
| title_fullStr | Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation |
| title_full_unstemmed | Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation |
| title_short | Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation |
| title_sort | isatuximab for delayed red cell engraftment after allogeneic hematopoietic cell transplantation |
| url | http://dx.doi.org/10.1155/2024/5790011 |
| work_keys_str_mv | AT marynauffal isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT stepheneng isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT andrewlin isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT alexanderchan isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT kathrynmazzerella isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT sergiogiralt isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT miguelangelperales isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation AT boglarkagyurkocza isatuximabfordelayedredcellengraftmentafterallogeneichematopoieticcelltransplantation |